Tomer Meir Salame

Tomer Meir Salame

Auto-generated profile, based on publicly available information

Tomer Meir Salame

The Weizmann Institute of Science

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2017 in Science
Verified
Journal Article
Open access
PDF file
CMChiara Medaglia
Chiara Medaglia
AGAmir Giladi
Amir Giladi
LSLiat Stoler-Barak
Liat Stoler-Barak
MGMarco De Giovanni
Marco De Giovanni
TSTomer Meir Salame
Tomer Meir Salame
IAIdo Amit
Ido Amit
Spatial information from NICHE-seq: Immune functions depend on the interactions of heterogeneous cells in a range of microenvironments in the body. Although information regarding immune cell function has been collected using single-cell RNA-sequencing methods, these techniques have traditionally lacked spatial information. Medaglia et al. describe NICHE-seq, a technique that allows the sorting and analysis of cells from within visually selected territories in transgenic mice that express photoactivatable green fluorescent protein. The method successfully identified T and B cell-specific niches in mouse lymph nodes and spleens after virus infection. The approach will allow us to bridge the gap between cellular and spatial information in studies of organs. Science , this issue p. 1622

4 April 2022 in Cell
Verified
Journal Article
Closed access
CGChamutal Gur
Chamutal Gur
SWShuang-Yin Wang
Shuang-Yin Wang
FSFadi Sheban
Fadi Sheban
MZMor Zada
Mor Zada
BLBaoguo Li
Baoguo Li
IAIdo Amit
Ido Amit

18 February 2022 in Immunity
Verified
Journal Article
Closed access
ABAdi Biram
Adi Biram
JLJingjing Liu
Jingjing Liu
HHHadas Hezroni
Hadas Hezroni
NDNatalia Davidzohn
Natalia Davidzohn
DSDominik Schmiedel
Dominik Schmiedel
ZSZiv Shulman
Ziv Shulman

15 November 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Donatella RomanielloDonatella Romaniello
Donatella Romaniello
LMLuigi Mazzeo
Luigi Mazzeo
MMMaicol Mancini
Maicol Mancini
IMIlaria Marrocco
Ilaria Marrocco
ANAshish Noronha
Ashish Noronha
YYYosef Yarden
Yosef Yarden
Purpose: Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), no targeted treatments are available for patients with lung cancer who lose sensitivity due to new mutations or bypass mechanisms. We examined in animals and in vitro an alternative therapeutic approach making use of antibodies. Experimental Design: An osimertinib-sensitive animal model of lung cancer, which rapidly develops drug resistance, has been employed. To overcome compensatory hyperactivation of ERK, which we previously reported, an anti-EGFR antibody (cetuximab) was combined with other antibodies, as well as with a subtherapeutic dose of osimertinib, and cancer cell apoptosis was assayed. Results: Our animal studies identified a combination of three clinically approved drugs, cetuximab, trastuzumab (an anti-HER2 mAb), and osimertinib (low dose), as an effective and long-lasting treatment that is able to prevent onset of resistance to osimertinib. A continuous schedule of concurrent treatment was sufficient for effective tumor inhibition and for prevention of relapses. Studies employing cultured cells and analyses of tumor extracts indicated that the combination of two mAbs and a subtherapeutic TKI dose sorted EGFR and HER2 for degradation; cooperatively enhanced apoptosis; inhibited activation of ERK; and reduced abundance of several bypass proteins, namely MET, AXL, and HER3. Conclusions: Our in vitro assays and animal studies identified an effective combination of clinically approved drugs that might overcome resistance to irreversible TKIs in clinical settings. The results we present attribute the long-lasting effect of the drug combination to simultaneous blockade of several well-characterized mechanisms of drug resistance. Clin Cancer Res; 1–12. ©2018 AACR.

18 December 2024 in Journal of Cell Biology
Verified
Journal Article
Open access
RVRosario Valenti
Rosario Valenti
YDYotam David
Yotam David
DEDunya Edilbi
Dunya Edilbi
BDBenjamin Dubreuil
Benjamin Dubreuil
ABAngela Boshnakovska
Angela Boshnakovska
MSMaya Schuldiner
Maya Schuldiner
Genome-wide collections of yeast strains, known as libraries, revolutionized the way systematic studies are carried out. Specifically, libraries that involve a cellular perturbation, such as the deletion collection, have facilitated key biological discoveries. However, short-term rewiring and long-term accumulation of suppressor mutations often obscure the functional consequences of such perturbations. We present the AID library which supplies “on demand” protein depletion to overcome these limitations. Here, each protein is tagged with a green fluorescent protein (GFP) and an auxin-inducible degron (AID), enabling rapid protein depletion that can be quantified systematically using the GFP element. We characterized the degradation response of all strains and demonstrated its utility by revisiting seminal yeast screens for genes involved in cell cycle progression as well as mitochondrial distribution and morphology. In addition to recapitulating known phenotypes, we also uncovered proteins with previously unrecognized roles in these central processes. Hence, our tool expands our knowledge of cellular biology and physiology by enabling access to phenotypes that are central to cellular physiology and therefore rapidly equilibrated.

20 November 2024 in Cancer Discovery
Verified
Journal Article
Open access
SSSapir Cohen Shvefel
Sapir Cohen Shvefel
JPJoy A. Pai
Joy A. Pai
YCYingying Cao
Yingying Cao
LPLipika R. Pal
Lipika R. Pal
OBOsnat Bartok
Osnat Bartok
YSYardena Samuels
Yardena Samuels
Low intratumor heterogeneity correlates with increased patient survival and immunotherapy response. However, even highly homogeneous tumors are variably aggressive, and the immunologic factors impacting aggressiveness remain understudied. In this study, we analyzed the mechanisms underlying immune escape in murine tumors with low intratumor heterogeneity. We used immunophenotyping and single-cell RNA sequencing to compare the temporal growth of in vivo transplanted, genetically similar, rejected and nonrejected single-cell clones. Nonrejected clones showed high infiltration of tumor-associated macrophages, lower T cell infiltration, and increased T cell exhaustion when compared with rejected clones. Comparative analysis of rejection-associated gene expression programs, combined with in vivo CRISPR knockout screens of candidate regulators, identified macrophage migration inhibitory factor (Mif) as a major contributor to preventing immune rejection. Mif knockout resulted in smaller tumors and reduced tumor-associated macrophage infiltration. These results were validated in patients with melanoma. Overall, our homogeneous tumor system can uncover factors regulating growth variability and identifies Mif as critical in aggressive melanoma. Significance: In this study, we find that Mif expression is associated with tumor growth and aggressiveness, specifically in tumors with low heterogeneity. These findings could facilitate the development of new strategies to treat patients with homogeneous, high MIF–expressing tumors that are unresponsive to immune checkpoint therapy.